Over the last decade or so, there has been a paradigm shift in the oncologic care of patients
with a range of solid tumour and haematologic malignancies, away from traditional cytotoxic …

In the last years, major progress occurred in heart failure (HF) management. Quadruple
therapy is now mandatory for all the patients with HF with reduced ejection fraction. Whilst …

ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

Abstract Immune-checkpoint-inhibitor (ICI)–associated myotoxicity involves the heart
(myocarditis) and skeletal muscles (myositis), which frequently occur concurrently and are …

Immune-related adverse events (irAEs) associated with immune checkpoint inhibitor (ICI)
therapy may vary substantially in their clinical presentation, including natural history …

BACKGROUND: Immune checkpoint inhibitors (ICIs) are approved for multiple cancers but
can result in ICI-associated myocarditis, an infrequent but life-threatening condition …

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by unleashing the
power of the immune system against malignant cells. However, their use is associated with a …

Immune checkpoint inhibitors (ICIs) and BRAF and MEK inhibitors (BRAFi/MEKi) have
drastically improved the outcome of melanoma patients. ICIs can induce myocarditis, a rare …

Background Immune checkpoint inhibitor (ICI)-related myocarditis is a rare but potentially
fatal adverse event that can occur following ICI exposure. Early diagnosis and treatment are …

The broad application of immune checkpoint inhibitors (ICIs) has led to significant gains in
cancer outcomes. By abrogating inhibitory signals, ICIs promote T cell targeting of cancer …